One Down, Two To Go For Adcetris’ Expansion In Lymphoma

Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.

Partners Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. are pushing aggressively to expand the antibody-drug conjugate Adcetris (brentuximab vedotin) in new lymphoma indications. The first of three ongoing Phase III trials has read out positively, but late-stage studies are continuing in what are expected to be the larger commercial opportunities.

The companies announced Aug. 1 that the Phase III ALCANZA trial, evaluating Adcetris in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically significant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.